Drug reference

Sevelamer

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1137, 1138

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

RENAGEL ® Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis ▶BY MOUTH ▶Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be given with meals and adjusted according to serum-phosphate concentration; usual dose 2.4–12 g daily in 3 divided doses RENVELA ® 2.4G ORAL POWDER SACHETS Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis | Hyperphosphataemia in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more ▶BY MOUTH ▶Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be taken with meals and adjusted according to serum-phosphate concentration every 2–4 weeks— consult product literature; usual dose 6 g daily in 3 divided doses RENVELA ® 800MG TABLETS Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis | Hyperphosphataemia in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more ▶BY MOUTH ▶Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be taken with meals and adjusted according to serum-phosphate concentration every 2–4 weeks; usual dose 6 g daily in 3 divided doses

PDF page 1137

Contra Indications

Bowel obstruction

PDF page 1137

Cautions

Gastro-intestinal disorders

PDF page 1137

National Funding Access Decisions

RENVELA ® 2.4G ORAL POWDER SACHETS Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (April 2011) that sevelamer carbonate (Renvela ®) is accepted for restricted use within NHS Scotland for the second-line management of hyperphosphataemia in adults receiving haemodialysis. RENVELA ® 800MG TABLETS Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (April 2011) that sevelamer carbonate (Renvela ®) is accepted for restricted use within NHS Scotland for the second-line management of hyperphosphataemia in adults receiving haemodialysis.

PDF page 1138

Safety

Side Effects

▶Common or very common Constipation. diarrhoea. gastrointestinal discomfort. gastrointestinal disorders. nausea. vomiting ▶Frequency not known Skin reactions

PDF pages 1137, 1138

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 1138

Breast Feeding

RENVELA ® 2.4G ORAL POWDER SACHETS Unlikely to be present in milk (however, manufacturer advises avoid). RENAGEL ® Manufacturer advises use only if potential beneﬁt outweighs risk. RENVELA ® 800MG TABLETS Unlikely to be present in milk (however, manufacturer advises avoid).

PDF page 1138

Dose and formulations

Directions For Administration

RENVELA ® 2.4G ORAL POWDER SACHETS Manufacturer advises each sachet should be dispersed in 60 mL water, or Blood and nutrition mixed with a small amount of cool food (100 g), prior to administration and discarded if unused after 30 minutes.

PDF page 1138

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder CAUTIONARY AND ADVISORY LABELS 13 ▶Renvela (Sanofi) Sevelamer carbonate 2.4 gram Renvela 2.4g oral powder sachets sugar-free | 60 sachet P £167.04 DT = £167.04 Tablet CAUTIONARY AND ADVISORY LABELS 25 EXCIPIENTS: May contain Propylene glycol ▶Renagel (Sanofi) Sevelamer 800 mg Renagel 800mg tablets | 180 tablet P £167.04 DT = £49.83 ▶Renvela (Sanofi) Sevelamer 800 mg Renvela 800mg tablets | 180 tablet P £167.04 DT = £49.83

PDF page 1138

Clinical care

Patient And Carer Advice

RENVELA ® 2.4G ORAL POWDER SACHETS Patients and carers should be advised on how to administer powder for oral suspension.

PDF page 1138

Dose text by age group

Adult

Initially 2.4–4.8 g daily in 3 divided doses, dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1137

Adult

Initially 2.4–4.8 g daily in 3 divided doses, dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1137

Adult

Initially 2.4–4.8 g daily in 3 divided doses, dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1137

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Sevelamer

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1137, 1138

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1137

Contra Indications

Bowel obstruction

PDF page 1137

Cautions

Gastro-intestinal disorders

PDF page 1137

National Funding Access Decisions

PDF page 1138

Safety

Side Effects

▶Common or very common Constipation. diarrhoea. gastrointestinal discomfort. gastrointestinal disorders. nausea. vomiting ▶Frequency not known Skin reactions

PDF pages 1137, 1138

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 1138

Breast Feeding

PDF page 1138

Dose and formulations

Directions For Administration

PDF page 1138

Medicinal Forms

PDF page 1138

Clinical care

Patient And Carer Advice

RENVELA ® 2.4G ORAL POWDER SACHETS Patients and carers should be advised on how to administer powder for oral suspension.

PDF page 1138

Dose text by age group

Adult

Initially 2.4–4.8 g daily in 3 divided doses, dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1137

Adult

Initially 2.4–4.8 g daily in 3 divided doses, dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1137

Adult

Initially 2.4–4.8 g daily in 3 divided doses, dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1137

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.